Targeting dormant leukaemia cells
Nature
May 12, 2008
A new role for a protein involved in leukaemia is described in Nature this week; the research demonstrates its potential as a therapeutic target to eradicate dormant leukaemia-initiating cells.
The promyelocytic leukaemia protein (PML) tumour suppressor is known to be involved in the development of some forms of leukaemia. Pier Paolo Pandolfi and colleagues identify a new and unexpected role for PML in the maintenance of both haematopoietic stem cells and leukaemia-initiating cells. They demonstrate, in mice, that targeting the protein with arsenic trioxide eliminates the cancer-initiating cells, thought to be resistant to chemotherapy and other therapies.
The team believes that their results present a new pharmacological approach to target cells that are missed by other therapies and therefore lead to disease relapse.
doi: 10.1038/nature07016
Research highlights
-
Jan 15
Environment: Seagrass meadows may facilitate marine plastic removal from the seaScientific Reports
-
Jan 15
Planetary Science: Mercury may have shrunk less than previously thoughtCommunications Earth＆Environment
-
Jan 13
Environment: Polyester fibres found to be widespread in the ArcticNature Communications
-
Dec 23
Planetary science: Over 100,000 new craters identified on the MoonNature Communications
-
Dec 22
Conservation: Agricultural expansion could cause widespread biodiversity declines by 2050Nature Sustainability
-
Dec 18
Geology: Alpine summits may have been ice-free during life of Tyrolean IcemanScientific Reports
